Latest Breaking News On - Murrayb stein - Page 1 : comparemela.com

Breakthrough Study Sheds Light on Post-Traumatic Stress Disorder

The Psychiatric Genetics Consortium (PGC), a consortium of researchers led by scientists at University of California San Diego School of Medicine has made significant advancements in the understanding of the neurobiology of post-traumatic stress diso

Yale universityUnited statesStanford universityUniversity of california san diegoSan diegoMclean hospitalCity ofUnited kingdomWesleyk thompsonNikolaosp daskalakisAndersm daleKarmelw choiCarole franzMatthews panizzonKarestanc koenenMurrayb stein

New Study Links Excess Cannabis Use to Numerous Health Problems

A comprehensive study conducted by researchers from Yale, involving the analysis of over one million individuals' genomes, has provided new insights into the biology of cannabis use disorder. This study also explores its connections to various psychiatric conditions, the tendency to abuse other subs

United statesKellym harringtonTodd lenczFrankr wendtJ michael gazianoRenato polimantiYairaz nunezJosephd deakJoel gelernterHowardj edenbergMegan cookePriya guptaDavidm hougaardDanielf leveyDora kollerEmmac johnson

bwog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bwog.com Daily Mail and Mail on Sunday newspapers.

New zealandSan diegoUnited statesUniversity of california san diegoEric juengstGabe lazaro munozMurrayb steinJosephine johnstonUniversity of north carolina chapel hillPublic healthResearch on ethicalUniversity of otagoHastings centerSocial implicationsBehavioral geneticsFriday forum

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held 28 September 2023 at 8:00 AM EST (10:00 PM AEST). Please click on the link to watch the replay: https://lifescievents.com/event/bnox/ ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 29, 2023 /PRNewswire/ Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced pos

San diegoUnited statesUnited kingdomUniversity of california san diegoSouth australiaSpyros papapetropoulosMurrayb steinPrnewswire bionomics limited nasdaqMerck co incAffairs san diego healthcare systemBionomics or companyPublic healthDrug administrationMontgomery sberg depression rating scaleInsomnia severity indexSheehan disability scale

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

University of california san diegoUnited statesUnited kingdomSan diegoSouth australiaSpyros papapetropoulosMurrayb steinExchange commissionCompany annual report on formAffairs san diego healthcare systemBionomics limited nasdaqDrug administrationPublic healthBionomics or companyInvestor centerMerck co inc